- 专利标题： OPTIMIZING T CELL DIFFERENTIATION STATE WITH MICRORNAS
-
申请号： US18293729申请日： 2022-08-09
-
公开(公告)号： US20240342280A1公开(公告)日： 2024-10-17
- 发明人: Erietta Stelekati , E. John Wherry , Joseph A. Fraietta
- 申请人： THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA , University of Miami
- 申请人地址： US PA Philadelphia
- 专利权人： THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA,University of Miami
- 当前专利权人： THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA,University of Miami
- 当前专利权人地址： US PA Philadelphia
- 国际申请： PCT/US22/74695 2022.08.09
- 进入国家日期： 2024-01-30
- 主分类号： A61K39/00
- IPC分类号： A61K39/00 ; A61P35/00 ; C07K14/705 ; C07K14/725 ; C07K16/28 ; C12N5/0783 ; C12N15/113
摘要：
The current invention includes compositions and methods comprising immune effector cells modified to express miR-29a for the purpose of resisting immune exhaustion. In various embodiments the transmembrane domain comprises a transmembrane region of a protein selected from the group consisting of a type I transmembrane protein, an alpha chain of a T cell receptor, a beta chain of a T cell receptor, a zeta chain of a T cell receptor, CD28, CD2, CD3 epsilon, CD45, CD4, CD5, CD7, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134 (OX-40), CD137 (4-1BB), CD154 (CD40L), CD278 (ICOS), CD357 (GITR), Toll-like receptor 1 (TLR1), TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, and TLR9.
信息查询
